Altogether, these results indicate that DYRK1A specific inhibition efficiently sensitizes tumors to chemotherapy treatment in preclinical colon cancer and TNBC models and suggest that DYRK1A inhibition could prove useful in the clinic if used in combination with G1/S-targeting chemotherapy drug combination treatments. Here, DYRK1A is linked to colonic neoplasm.